Jianfeng Xu

Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.

Federal Grant PI High Impact

Researcher

Arkansas State University

Also affiliated: Hebei Agricultural University (2005–2025); Shanghai University (2017); Beth Israel Deaconess Medical Center (2005–2013); Shanghai Medical College of Fudan University (2008); Endeavor Health (2016–2020); Harvard University (2005–2013); Nanjing Normal University (2005); Harbin Medical University (2008); Sun Yat-sen University (2013–2015); State Street (United States) (2007); Xiamen University (2014–2015); Chinese Academy of Sciences (1998); Chinese Academy of Medical Sciences & Peking Union Medical College (2025); Peking University (2016–2017); Huazhong Agricultural University (2024); Cornell University (2009); Fudan University (2012–2016); Dalian University of Technology (1998); Wenzhou Medical University (2020); Massachusetts General Hospital (2012–2013); National Cancer Center (2025); Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University (2020); Shanghai Public Health Clinical Center (2016); Ohio University (2000–2011); Taixing People's Hospital (2023); Shaoxing Second Hospital (2012); Zhongshan Hospital of Xiamen University (2014); Zhongshan Hospital (2008–2015); The First Affiliated Hospital, Sun Yat-sen University (2013–2015); Peking University First Hospital (2016–2017); Zhejiang Entry-Exit Inspection and Quarantine Bureau (2015); Affiliated Zhongshan Hospital of Dalian University (2025); PharmacoGenetics (China) (2012); Immunovaccine (Canada) (2007); Hebei Mental Health Center (2024); Arkansas Biosciences Institute (2010–2025); Lilly (China) (2015–2019); Chinese Research Academy of Environmental Sciences (2017–2021); Huashan Hospital (2016); Tris Pharma (United States) (2012); State Key Laboratory of Genetic Engineering (2008); Shanghai Ocean University (2018–2025); University of Bath (2019); China Jiliang University (2015); Liverpool John Moores University (2019); Yangzhou University (2024); Ministry of Industry and Information Technology (2024)

Faculty Researcher

36 h-index 135 pubs 4,771 cited

Upstream record may be merged OpenAlex, the source of these figures, lists 48 institutions in 4 countries for this author record — a pattern that usually means it combines several researchers with similar names. The totals above may include work by other people.

Research Areas

Biomedical Subjects

Links

ORCID Google Scholar Lab Website

OverviewAI-generated summary

Jianfeng Xu's research focuses on leveraging plant cells for the production of therapeutic proteins and investigating molecular mechanisms in cancer. He has received federal funding for projects related to engineering plant cells to produce novel designer biologics for the oral treatment of ulcerative colitis, and for enhancing protein production and applications through GPI-anchored proteins in plant cells. Additionally, he is a Co-PI on a grant for acquiring an X-Ray Diffractometer to support materials and biomaterials research and education.

His recent publications explore diverse areas including the cellular engineering of plants for improved therapeutic protein production, the role of Apolipoprotein L3 in enhancing CD8+ T cell antitumor immunity in colorectal cancer by promoting ferroptosis, and the regulation of epithelial-mesenchymal transition by HERC3 in colorectal cancer metastasis. Other publications address gut microbiota signatures in colorectal cancer patients, HER2 positivity as a prognostic biomarker, and radiomics-based fusion models for predicting treatment response in colorectal cancer liver metastases.

Xu holds a high-impact researcher designation, evidenced by his h-index of 35 and over 4,600 citations across 135 publications. His collaborations within Arkansas State University include shared publications with Paula PerezSanchez, Jacqueline Vargas Ulloa, Auburn Ramsey, and Jennifer Y. Xie. He maintains an active laboratory website.

Metrics

h-index: 36
Publications: 135
Citations: 4,771

Selected Publications

Advances in promoter engineering strategies for enhanced recombinant protein expression in plants (2026)

Frontiers in Plant Science 6 citations DOI OpenAlex
Morphology and bioproduction potential of DCB-induced cell wall-deficient tobacco BY-2 cells and transcriptomic analysis (2025)

DOI OpenAlex
Unlocking the full potential of plant cell-based production for valuable proteins: Challenges and innovative strategies (2025)

Biotechnology Advances 8 citations DOI OpenAlex
Acidothermus cellulolyticus E1 endoglucanase expressed in planta undergoes extensive hydroxyproline-O-glycosylation and exhibits enhanced impact on biomass digestibility (2024)

Plant Cell Reports 4 citations DOI OpenAlex
Abstract 2377 Thermophilic E1 endoglucanase from Acidothermus cellulolyticus undergoes extensive hydroxyproline-O-glycosylation when expressed in planta (2024)

DOI OpenAlex
Harnessing the Power of Plants: A Green Factory for Bioactive Compounds (2023)

Life 4 citations DOI OpenAlex
Intracellular trafficking and glycosylation of hydroxyproline-O-glycosylation module in tobacco BY-2 cells is dependent on medium composition and transcriptome analysis (2023)

Scientific Reports 4 citations DOI OpenAlex
Arabinogalactan Structures of Repetitive Serine-Hydroxyproline Glycomodule Expressed by Arabidopsis Cell Suspension Cultures (2023)

Plants 5 citations DOI OpenAlex
Plants as Biofactories for Therapeutic Proteins and Antiviral Compounds to Combat COVID-19 (2023)

Life 22 citations DOI OpenAlex
CAP1 (cyclase-associated protein 1) mediates the cyclic AMP signals that activate Rap1 in stimulating matrix adhesion of colon cancer cells (2023)

Cellular Signalling 15 citations DOI OpenAlex